Clinical Trial Update: Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating masitinib in combination with docetaxel for metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Metastatic Castrate Resistant Prostate Cancer | Phase 3 | Status: COMPLETED